Caribou Biosciences (CRBU) Total Debt (2020)
Caribou Biosciences (CRBU) posted quarterly Total Debt of $924000.0 for Q4 2020.
Caribou Biosciences (CRBU) Total Debt (2020) Analysis & Trends
Caribou Biosciences (CRBU) has reported Total Debt for 1 consecutive years, with $924000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Total Debt changed N/A year-over-year to $924000.0; the TTM figure through Dec 2020 stood at $924000.0 (changed N/A YoY), while the FY2020 annual figure was $924000.0, changed N/A from the prior year.
- Total Debt steadied at $924000.0 in Q4 2020 per CRBU's latest filing.
- Across five years, Total Debt topped out at $924000.0 in Q4 2020 and bottomed at $924000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.34 Bn |
| 10 | Caribou Biosciences | 165.11 Mn | 52.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 924,000.00 |